Regenxbio Signs an Exclusive Development and Commercialization Agreement with Neurimmune for AAV Gene Therapies Targeting Neurodegenerative Diseases

Shots:

• Regenxbio and Neurimmune enter into a collaboration to develop vectorized Ab by combining antibodies identified using Neurimmune’s reverse translational medicine platform with Regenxbio’s NAV technology platform for chronic neuro-degenerative diseases including tauopathies
• The companies will jointly develop & commercialize AVV gene therapies with equal development cost-sharing with an initial focus on tauopathies. Following initial research, each company has an option to co-develop & co-commercialize each target or to elect to receive royalties in lieu of each target
• Neurimmune’s RTM technology translates the genetic information from human’s WBC into selective Abs. Regenxbio’s technology involves the development of one-time treatments in multiple disease areas based on AAV-mediated AB delivery using NAV Vectors used to treat chronic diseases

Click here to­ read full press release/article | Ref: Regenxbio | Image: Neurimmune